Skip to main content
SpringerLink
Log in
Book cover

Skin of Color pp 139–160Cite as

Disorders of Hyperpigmentation

  • Chapter
  • First Online:

  • 2231 Accesses

Abstract

Acquired disorders of hyperpigmentation affect individuals of all skin types. However, pigmentary lesions may be more visible in skin of color and are often resistant to treatment. Dyschromias, in addition to acne, eczema, alopecia, and seborrheic dermatitis, are among the most common diagnoses in black patients seen by dermatologists. Etiology, diagnosis, treatment, and recommendations for melasma, postinflammatory hyperpigmentation, nevus of Ota/Ito, and periorbital hypermelanosis are reviewed.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Halder RM. Ethnic skin disorders overview. J Am Acad Dermatol. 2003;48 suppl 6:143–8.

    Article  Google Scholar 

  2. Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a ­comparative practice survey. Cutis. 2007;80:387–94.

    PubMed  Google Scholar 

  3. Sivayathorn A. Melasma in orientals. Clin Drug Invest. 1995;10 suppl 2:34–40.

    Google Scholar 

  4. Hann SK, Im S, Chung WS, et al. Pigmentary disorders in the South East. Dermatol Clin. 2007;25:431–8.

    Article  PubMed  CAS  Google Scholar 

  5. Moin A, et al. Prevalence and awareness of melasma during pregnancy. Int J Dermatol. 2006;45:285.

    Article  PubMed  Google Scholar 

  6. Werlinger KD, Jabery Z, Fallah N. Prevalence of self-diagnosed melasma among premenopausal Latino women in Dallas and Fort Worth, Tex. Arch Dermatol. 2007;143:424–5.

    PubMed  Google Scholar 

  7. Goh CL, Dlova CN. A retrospective study on the clinical presentation and treatment outcome of melasma in a tertiary dermatological referral centre in Singapore. Singap Med J. 1999;40: 455–8.

    CAS  Google Scholar 

  8. Vasquez M, Maldonado H, Benmaman C, et al. Melasma in men: a clinical and histologic study. Int J Dermatol. 1988;27:25.

    Article  Google Scholar 

  9. Resnik S. Melasma induced by oral contraceptive drugs. JAMA. 1967;199:95.

    Article  Google Scholar 

  10. Lieberman R, Moy L. Estrogen receptor expression in melasma: results from facial skin of affected patients. J Drugs Dermatol. 2008;7(5):463–5.

    PubMed  Google Scholar 

  11. Jee SH, Lee SY, Chiu HC, et al. Effects of estrogen and estrogen receptor in normal human melanocytes. Biochem Biophys Res Commun. 1994;199:1407–12.

    Article  PubMed  CAS  Google Scholar 

  12. Im S, Kim J, On WY, et al. Increased expression of α-melanocyte-stimulating hormone in the lesional skin of melasma. Br J Dermatol. 2007;146:165–7.

    Google Scholar 

  13. Pandya AG, Guevara IL. Disorders of hyperpigmentation. Dermatol Clin. 2000;18:91–7.

    Article  PubMed  CAS  Google Scholar 

  14. Rigopoulos D, Gregoriou S, Katsambas A. Hyperpigmentation and melasma. J Cosmet Dermatol. 2007;6:195–202.

    Article  PubMed  CAS  Google Scholar 

  15. Sanchez NP, Pathak MA, Sato S, et al. Melasma: a clinical, light microscopic, ultrastructural and immunofluorescence study. J Am Acad Dermatol. 1981;4(6):698–709.

    Article  PubMed  CAS  Google Scholar 

  16. Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am J Dermatopathol. 2005;27:96–101.

    Article  PubMed  Google Scholar 

  17. Balkrishnan R, McMichael AJ, Camacho FT, et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol. 2003;149:572.

    Article  PubMed  CAS  Google Scholar 

  18. Dominguez AR, Balkrishnan R, Ellzey AR, et al. Melasma in Latina patients: cross-cultural adaptation and validation of a quality-of-life questionnaire in Spanish language. J Am Acad Dermatol. 2006;55:59–66.

    Article  PubMed  Google Scholar 

  19. Cestari TF, Hexsel D, Viegas ML, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy. Br J Dermatol. 2007;156:13–20.

    Article  Google Scholar 

  20. Pathak MA, Riley FC, Fitzpatrick TB, et al. Melanogenesis in human skin following exposure to long-wave ultraviolet and visible light. J Invest Dermatol. 1962;39:435.

    PubMed  CAS  Google Scholar 

  21. Mahmoud BH, Hexsel CL, Hamzavi IH, et al. Effects of visible light on the skin. Photochem Photobiol. 2008;84:450–62.

    Article  PubMed  CAS  Google Scholar 

  22. Mahmoud BH, et al. Photobiologic effects of long wavelength UVA and visible light on melanocompetent skin. J Invest Dermatol. 2009;129 suppl 1:125.

    Google Scholar 

  23. Lakhdar H, Zouhair K, Khadir K, et al. Evaluation of the effectiveness of a broad-spectrum sunscreen in the prevention of chloasma in pregnant women. J Eur Acad Dermatol Venereol. 2007;21:738–42.

    Article  PubMed  CAS  Google Scholar 

  24. Benchikhi H, Razoki H, Lakhdar H. Sunscreens: use in pregnant women at Casablanca. Ann Dermatol Venereol. 2002;129:387–90.

    PubMed  CAS  Google Scholar 

  25. Vazquez M, Sanchez JL. The efficacy of a broad-spectrum sunscreen in the treatment of melasma. Cutis. 1983;32:92.

    PubMed  CAS  Google Scholar 

  26. Ennes SBP, et al. A double-blind, comparative, placebo-controlled study of the efficacy and tolerability of hydroquinone as a depigmenting agent in melasma. J Dermatol Treat. 2000;11:173–9.

    Article  CAS  Google Scholar 

  27. Charlin R, Barcaui CB, Kac BK, et al. Hydroquinone-induced exogenous ochronosis: a report of four cases and usefulness of dermoscopy. Int J Dermatol. 2008;47:19–23.

    Article  PubMed  Google Scholar 

  28. Nordlund JJ, Grimes P, Ortonne JP, et al. The safety of hydroquinone. J Eur Acad Dermatol Venereol. 2006;20:781–7.

    Article  PubMed  CAS  Google Scholar 

  29. Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther. 2007;20:308–13.

    Article  PubMed  Google Scholar 

  30. Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol. 1975;111:40–8.

    Article  PubMed  CAS  Google Scholar 

  31. Taylor S, Torok H, Jones T, et al. Efficacy and safety of a new triple combination agent for the treatment of facial melasma. Cutis. 2003;72:67–72.

    PubMed  Google Scholar 

  32. Torok H, Jones T, Rich P, et al. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. Cutis. 2005;75:57–62.

    PubMed  Google Scholar 

  33. Grimes P, Kelly AP, Torok H, et al. Community-based trial of a triple-combination agent for the treatment of facial melasma. Cutis. 2006;77:177–84.

    PubMed  Google Scholar 

  34. Chan R, Park KC, Lee MH, et al. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol. 2008;159:697–703.

    PubMed  CAS  Google Scholar 

  35. Del Rosso JQ. The use of topical azelaic acid for common skin disorders other than inflammatory rosacea. Cutis. 2006;77((2 suppl)):22–4.

    PubMed  Google Scholar 

  36. Verallo-Rowell VM, Verallo V, Graupe K, et al. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol (Stockh). 1989;143 ((suppl)):58–61.

    CAS  Google Scholar 

  37. Balina LM, Graupe K, et al. The treatment of melasma: 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol. 1991;30:893.

    Article  PubMed  CAS  Google Scholar 

  38. Graupe K, Verallo-Rowell VM, Verallo V, et al. Combined use of 20% azelaic acid cream and 0.05% tretinoin in topical treatment of melasma. J Dermatol Treat. 1996;7:235–7.

    Article  Google Scholar 

  39. Garcia A, Fulton JE. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg. 1996;22:443.

    Article  PubMed  CAS  Google Scholar 

  40. Lim JT. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg. 1999;25:282–4.

    Article  PubMed  CAS  Google Scholar 

  41. Gupta RR, Mahajan BB, Garg G, et al. Chemical peeling – evaluation of glycolic acid in ­varying concentrations and time intervals. Cosmetol. 2001;67:28–9.

    CAS  Google Scholar 

  42. Sarkar R, Kaur C, Ghalla M, et al. The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study. Dermatol Surg. 2002;28:828–32.

    Article  PubMed  Google Scholar 

  43. Erbil H, Sezer E, Tastan B, et al. Efficacy and safety of serial glycolic acid peels and a topical regimen in the treatment of recalcitrant melasma. J Dermatol. 2007;34:25–30.

    Article  PubMed  CAS  Google Scholar 

  44. Hurley ME, Guevara IL, Gonzales RM, et al. Efficacy of glycolic acid peels in the treatment of melasma. Arch Dermatol. 2002;138:1578.

    Article  PubMed  Google Scholar 

  45. Garg VK, Sarkar R, Agarwal R, et al. Comparative evaluation of beneficiary effects of priming agents (2% hydroquinone and 0.025% retinoic acid) in the treatment of melasma with glycolic acid peels. Dermatol Surg. 2008;34:1032–9.

    Article  PubMed  CAS  Google Scholar 

  46. Grimes P. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg. 1999;25:18.

    Article  PubMed  CAS  Google Scholar 

  47. Lawrence N, Cox SE, Brody HJ. Treatment of melasma with Jessner’s solution versus glycolic acid: a comparison of clinical efficacy and evaluation of the predictive ability of Wood’s light examination. J Am Acad Dermatol. 1997;36:589–93.

    Article  PubMed  CAS  Google Scholar 

  48. Sharquie KE, Al-Tikreety MM, Al-Mashhadani SA. Lactic acid chemical peels as a new therapeutic modality in melasma in comparison to Jessner’s solution chemical peels. Dermatol Surg. 2006;32:1429–36.

    Article  PubMed  CAS  Google Scholar 

  49. Kunachak S, Leelaudomlipi P, Wongwaisayawan S. Dermabrasion: a curative treatment for melasma. Aesthetic Plast Surg. 2001;25:114–7.

    Article  PubMed  CAS  Google Scholar 

  50. Bhalla M, Thami G. Microdermabrasion: reappraisal and brief review of literature. Dermatol Surg. 2006;32:809–14.

    Article  PubMed  CAS  Google Scholar 

  51. Karimipour DJ, Karimipour G, Orringer JS. Microdermabrasion: an evidence-based review. Plast Reconstr Surg. 2010;125:372.

    Article  PubMed  CAS  Google Scholar 

  52. Tse Y, Levine VJ, McClain SA, et al. The removal of cutaneous pigmented lesions with the Q-switched ruby laser and the Q-switched neodymium:yttrium-aluminum-garnet laser: a comparative study. J Dermatol Surg Oncol. 1994;20:795.

    PubMed  CAS  Google Scholar 

  53. Polnikorn N. Treatment of refractory dermal melasma with the MedLite C6 Q-switched Nd:YAG laser: two case reports. J Cosmet Laser Ther. 2008;10:167–73.

    Article  PubMed  Google Scholar 

  54. Manaloto RMP, Alster T. Erbium:YAG laser resurfacing for refractory melasma. Dermatol Surg. 1999;25:121.

    Article  PubMed  CAS  Google Scholar 

  55. Ko NY, Ahn HH, Kim SN, et al. Analysis of erythema after Er:YAG laser skin resurfacing. Dermatol Surg. 2007;33:1322–7.

    Article  PubMed  CAS  Google Scholar 

  56. Rokhsar CK, Fitzpatrick RE. The treatment of melasma with fractional photothermolysis: a pilot study. Dermatol Surg. 2005;31:1645–50.

    Article  PubMed  CAS  Google Scholar 

  57. Graber EM, Tanzi EL, Alster TS. Side effects and complications of fractional laser photothermolysis: experience with 961 treatments. Dermatol Surg. 2008;34:301–5.

    Article  PubMed  CAS  Google Scholar 

  58. Goldberg DJ, Berlin AL, Phelps R. Histologic and ultrastructural analysis of melasma after fractional resurfacing. Lasers Surg Med. 2008;40:134–8.

    Article  PubMed  Google Scholar 

  59. Wang CC, Hui CY, Sue YM, et al. Intense pulsed light for the treatment of refractory melasma in Asian patients. Dermatol Surg. 2004;30:1196–200.

    Article  PubMed  Google Scholar 

  60. Li YH, Chen JZ, Wei HC, et al. Efficacy and safety of intense pulsed light in treatment of melasma in Chinese patients. Dermatol Surg. 2008;34:693–701.

    Article  PubMed  CAS  Google Scholar 

  61. Sriwiriyanont P, Ohuchi A, Hachiya A, et al. Interaction between stem cell factor and endothelin-1: effects on melanogenesis in human skin xenografts. Lab Invest. 2006;86:1115–25.

    PubMed  CAS  Google Scholar 

  62. Ruiz-Maldonado R, Orozco-Covarrubias ML. Postinflammatory hypopigmentation and hyperpigmentation. Semin Cutan Med Surg. 1997;16:36–43.

    Article  PubMed  CAS  Google Scholar 

  63. Nordlund JJ. Postinflammatory hyperpigmentation. Dermatol Clin. 1988;6:185.

    PubMed  CAS  Google Scholar 

  64. Kim NY, Pandya AG. Pigmentary diseases. Office Dermatol. 1998;82:1185–207.

    CAS  Google Scholar 

  65. Bulengo-Ransby S, Griffiths CD, Kimbrough-Green CK, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med. 1993;328:1438–43.

    Article  PubMed  CAS  Google Scholar 

  66. Grimes P. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation. Cutis. 2004;74:362–8.

    PubMed  Google Scholar 

  67. Baumann L, Grimes P, Pandya AG, Rendon M, Taylor S. Poster #1887, World congress of dermatology. Buenos Aires; 30 Sept–5 Oct 2007.

    Google Scholar 

  68. Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. Cutis. 2006;77:45–50.

    PubMed  Google Scholar 

  69. Burns RL, Prevost-Blank PL, Lawry MA, et al. Glycolic acid peels for postinflammatory hyperpigmentation in black patients. Dermatol Surg. 1997;23:171–5.

    Article  PubMed  CAS  Google Scholar 

  70. Joshi SS, Boone SL, Alam M, et al. Effectiveness, safety, and effect on quality of life of topical salicylic acid peels for treatment of postinflammatory hyperpigmentation in dark skin. Dermatol Surg. 2009;35:638–44.

    Article  PubMed  CAS  Google Scholar 

  71. Ahn HH, Kim IH. Whitening effect of salicylic acid peels in Asian patients. Dermatol Surg. 2006;32:372–5.

    Article  PubMed  CAS  Google Scholar 

  72. Garg VK, Sinha S, Sarkar R. Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. Dermatol Surg. 2009;35:59–65.

    Article  PubMed  CAS  Google Scholar 

  73. Qian Y, Zakov ZN, Schoenfield L, et al. Iris melanoma arising in iris nevus in oculo (dermal) melanocytosis. Surv Ophthalmol. 2008;53:411–5.

    Article  PubMed  Google Scholar 

  74. Sekar S, Kuruvila M, Pai HS. Nevus of Ota: a series of 15 cases. Indian J Dermatol Venereol Leprol. 2008;74:125–7.

    Article  PubMed  Google Scholar 

  75. Torres JE, Sanchez JL. Melasma and other disorders of hyperpigmentation. In: Arndt KA, LeBoit PE, Robinson JK, Wintroub BU, editors. Cutaneous medicine and surgery, vol. 2. Philadelphia: W.B. Saunders; 1996. p. 1239–40.

    Google Scholar 

  76. Hidano A, Kajima H, Ikeda S, et al. Natural history of nevus of Ota. Arch Dermatol. 1967;95:187–95.

    Article  PubMed  CAS  Google Scholar 

  77. Agero AL, Lahmar JJ, Holzborn RM, et al. Naevus of Ota presenting in two generations: a mother and daughter. J Eur Acad Dermatol Venereol. 2009;23:102–4.

    Article  PubMed  CAS  Google Scholar 

  78. Sinha S, Cohen PJ, Schwartz RA. Nevus of ota in children. Cutis. 2008;82:25–9.

    PubMed  Google Scholar 

  79. Chan HH, Lam LK, Wong DS, et al. Nevus of ota: a new classification based on the response to laser treatment. Lasers Surg Med. 2001;28:267–72.

    Article  PubMed  CAS  Google Scholar 

  80. Hirayama T, Suzuki T. A new classification of Ota’s nevus based on histopathological features. Dermatologica. 1991;183:169–72.

    Article  PubMed  CAS  Google Scholar 

  81. Mosher DB, Fitzpatrick TB, Ortonne J-P, Hori Y. Hypomelanoses and hypermelanoses. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB, editors. Fitzpatrick’s dermatology in general medicine. 5th ed. New York: McGraw-Hill; 1999. p. 1004.

    Google Scholar 

  82. Watanabe S. Basics of laser application to dermatology. Arch Dermatol Res. 2008;300 suppl 1:S21–30.

    Article  PubMed  Google Scholar 

  83. Kagami S, Asahina A, Watanabe R, et al. Treatment of 153 Japanese patients with Q-switched alexandrite laser. Lasers Med Sci. 2007;22:159–63.

    Article  PubMed  Google Scholar 

  84. Wang HW, Liu UH, Zhang GK, et al. Analysis of 602 Chinese cases of nevus of Ota and the treatment results treated by Q-switched alexandrite laser. Dermatol Surg. 2007;33:455–60.

    Article  PubMed  CAS  Google Scholar 

  85. Kang W, Lee E, Choi GS. Treatment of Ota’s nevus by Q-switched alexandrite laser: therapeutic outcome in relation to clinical and histopathological findings. Eur J Dermatol. 1999;9: 639–43.

    PubMed  CAS  Google Scholar 

  86. Chan HH, Leung RS, Ying SY, et al. Recurrence of nevus of Ota after successful treatment with Q-switched lasers. Arch Dermatol. 2000;136:1175–6.

    Article  PubMed  CAS  Google Scholar 

  87. Trindade F, Cabecadas J, Rosa J. Surgical management of the eyelid and bulbar conjunctiva in a patient with nevus of Ota. J Eur Acad Dermatol Venereol. 2008;22:618–20.

    Article  PubMed  CAS  Google Scholar 

  88. Goodman RM, Belcher RW. Periorbital hyperpigmentation. Arch Dermatol. 1969;100: 169–74.

    Article  PubMed  CAS  Google Scholar 

  89. Malakar S, Lahiri K, Banerjee U, et al. Periorbital melanosis is an extension of pigmentary demarcation line-F on face. Indian J Dermatol Venereol Leprol. 2007;73:323–5.

    Article  PubMed  Google Scholar 

  90. Selmanowitz VJ, Krivo JM. Pigmentary demarcation lines: comparison of Negroes with Japanese. Br J Dermatol. 1975;93:371–7.

    Article  PubMed  CAS  Google Scholar 

  91. Somani VK, Razvi F, Sita VN. Pigmentary demarcation lines over the face. Indian J Dermatol Venereol Leprol. 2005;70:336–41.

    Google Scholar 

  92. West TB, Alster TS. Improvement of infraorbital hyperpigmentation following carbon dioxide laser resurfacing. Dermatol Surg. 1998;24:615–6.

    Article  PubMed  CAS  Google Scholar 

  93. Momosawa A, Kurita M, Miyamoto S, et al. Combined therapy using Q-switched ruby laser and bleaching treatment with tretinoin and hydroquinone for periorbital skin hyperpigmentation in Asians. Plast Reconstr Surg. 2008;121:282–8.

    Article  PubMed  CAS  Google Scholar 

  94. Lowe NJ, Wieder JM, Shorr N, et al. Infraorbital pigmented skin: preliminary observations of laser therapy. Dermatol Surg. 1995;21:767.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 3031 W. Grand Blvd, 8th floor, Detroit, MI, 48202, USA

    So Yeon Paek M.D.

  2. Henry Ford Hospital, Detroit, MI, USA

    So Yeon Paek M.D.

  3. Department of Dermatology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9190, USA

    Amit G. Pandya M.D.

Authors
  1. So Yeon Paek M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amit G. Pandya M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to So Yeon Paek M.D. .

Editor information

Editors and Affiliations

  1. Department of Dermatology, St. Luke’s Roosevelt Hospital, Skin of Color Center, New York, 10025, New York, USA

    Andrew F. Alexis

  2. Rush University, Department of Dermatology, Chicago, 60602, Illinois, USA

    Victoria H. Barbosa

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Paek, S.Y., Pandya, A.G. (2013). Disorders of Hyperpigmentation. In: Alexis, A., Barbosa, V. (eds) Skin of Color. Springer, New York, NY. https://doi.org/10.1007/978-0-387-84929-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-84929-4_8

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-84928-7

  • Online ISBN: 978-0-387-84929-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation